Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 8/20 | 0.60 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.60 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.60 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.60 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317696 | 0.86 | HRH3 (0.59) | PRKAA2HDAC1MEN1KMT2AATM | |
| SCHEMBL3315806 | 0.85 | LMNA (0.51) | PRKAA2MEN1KMT2AATM | |
| SCHEMBL3314013 | 0.85 | KMT2A (0.50) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL3313636 | 0.84 | ALDH1A1 (0.47) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL3318698 | 0.83 | SIGMAR1 (0.55) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL3317378 | 0.83 | MEN1 (0.69) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL3311748 | 0.82 | HIF1A (0.60) | — | |
| SCHEMBL3321202 | 0.82 | GRM2 (0.50) | SIGMAR1MEN1KMT2AATM | |
| SCHEMBL5037300 | 0.80 | PLA2G10 (0.58) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1126310 | 0.78 | SIGMAR1 (0.60) | SIGMAR1GAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | claimed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| US-8815901-B2 | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-8273882-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | PRKAA2 363/4885PRKAB2 1082/4885PRKAG1 1224/4885 |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | PRKAA2 420/4885PRKAB2 873/4885PRKAG1 819/4885 |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | PRKAA2 420/4885PRKAB2 873/4885PRKAG1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.